Pomegra
Healthcare
MAJOR
6d ago5 min read
Moderna (MRNA) Hits 52-Week High Before Q3 Earnings
Moderna stock jumped 13% to $258.38 before its Q3 earnings, lifted by a WHO Ebola vaccine nod and cancer-vaccine momentum, extending a 600%-plus gain this year.
Company hub
MRNA stock news & analysis
Everything Pomegra has published on MRNA: 16 news articles and 9 market briefs, newest first.
Market briefs on MRNA
- Moderna Stock Jumps 9% After Q3 Earnings Beat
Moderna (MRNA) raised its 2026 revenue growth outlook to 15%-25% from up to 10% as quarterly sales rose 29%
6d ago
- AMD Stock Falls 10.9% Ahead of Earnings in Tech Sell-Off
AMD (AMD) reports Tuesday; Super Micro (SMCI) pre-announced up to $19.5B in sales amid AI demand doubts.
Nov 2
- Moderna Stock Falls 17% After Cancer Vaccine Data Leak
Moderna (MRNA) slid another 1.3% Friday to $200 as investors weighed a 42% cut in melanoma recurrence risk.
Oct 26
- Moderna Stock Falls 25% After Melanoma Vaccine Data Leak
Moderna (MRNA) fell as Merck slipped up to 3.9% after leaked data showed a 42% lower melanoma relapse risk.
Oct 22
- Moderna Stock Rises 4.4% as ESMO Cancer Vaccine Data Nears
Moderna (MRNA) is up over 600% this year after joining the Nasdaq-100, with Phase 3 data due Saturday.
Oct 19
- Moderna and Novavax jump 14–16% on Friday as biotech rallies on a federal cancer-vaccine push
The Friday gains came days after a plague-scare spike faded. Sources tie them mainly to a report on a national cancer-vaccine effort, not to the Russian plague case or Vaxcyte's trial result.
Oct 12
- Moderna Stock Rises 4.8% as Nasdaq-100 Entry Nears
Moderna (MRNA) is up more than 540% in 2026 as investors await Phase 3 cancer vaccine data on Oct. 24.
Oct 8
- Moderna (MRNA) Stock Jumps 7%: Latest News Before Cancer Data
Moderna (MRNA) is up nearly 600% in 2026 as traders position for full October 24 melanoma trial results. Latest MRNA stock news and what to watch.
Oct 5
- Moderna Stock Falls 6% After Citi Downgrade to Sell
Moderna (MRNA) sank from $203.46 to about $191 as Citi said a 222% rally assumes unrealistic cancer sales.
Sep 30
MRNA news
Technology
NOTABLE
Nov 26 min read
Tempus AI Q3 2026: Record $411.5M Revenue, Guidance Up
Tempus AI stock (TEM) rose after record Q3 2026 revenue of $411.5 million and a raised full-year outlook of about $1.6 billion, extending a September rally.
Healthcare
MAJOR
Oct 264 min read
Moderna Stock Falls 8% After Melanoma Vaccine Data Leak
Moderna (MRNA) shares fell another 8% on Monday after leaked melanoma vaccine data showed a 42% cut in recurrence or death risk, extending a selloff in biotech cancer stocks.
Healthcare
MAJOR
Oct 224 min read
Moderna Falls 25% as Leaked Melanoma Data Spooks Investors
Moderna shares fell as much as 25% after early-leaked Phase 3 melanoma vaccine data showed a 42% cut in recurrence risk, below Wall Street's lofty expectations.
Healthcare
MAJOR
Oct 215 min read
Moderna Stock Jumps 7% Ahead of Madrid Melanoma Data
Moderna rose 7% to $241.89 and Bristol Myers Squibb 5% as biotech cancer stocks rallied before Phase 3 melanoma vaccine data in Madrid on October 24.
Healthcare
NOTABLE
Oct 124 min read
Moderna Jumps 14% on Federal Cancer Vaccine Push
Moderna rose 14% to $225, its highest since January 2022, as a planned federal cancer vaccine push also lifted Pfizer, BioNTech and Merck shares on Friday.
Healthcare
NOTABLE
Oct 74 min read
Moderna Stock Falls 6% After Nasdaq-100 Rally
Moderna (MRNA) shares fell about 6% on profit-taking after a 52-week high, days before the biotech replaces Warner Bros. Discovery in the Nasdaq-100 on Oct. 9.
Markets
NOTABLE
Oct 24 min read
Moderna (MRNA) Joins Nasdaq-100 on Oct. 9 After Sixfold Run
Moderna replaces Warner Bros. Discovery in the Nasdaq-100 on Oct. 9 after a sixfold share surge, forcing index funds such as Nasdaq QQQ to buy the stock.
Healthcare
NOTABLE
Sep 304 min read
Moderna (MRNA) Drops 6% as Citi Downgrades to Sell
Moderna shares fell about 6% to near $190 after Citi cut the stock to Sell with an $80 target, saying a 223% rally overshot what cancer vaccine sales can justify.
Markets
SEISMIC
Sep 256 min read
MRNA Hits 52-Week High on mRNA Cancer Vaccine Win
Moderna's Phase 3 INTerpath-001 trial confirms its personalized mRNA melanoma vaccine cut recurrence and distant metastasis, lifting shares above $87 and validating a multi-year pivot to oncology.
Markets
SEISMIC
Sep 96 min read
Moderna Cancer Vaccine Wins Phase 3, Gets Sell Rating
Moderna's intismeran-Keytruda combination became the first cancer vaccine to clear a pivotal trial, yet Rothschild & Co. Redburn cut MRNA to Sell from Neutral on valuation, citing a share price…
Markets
SEISMIC
Sep 77 min read
MRNA: Biotech's Fastest Boom-Bust of 2026
Moderna's mRNA melanoma vaccine posted the first Phase 3 oncology success ever, lifting MRNA 177% before a Sell call and a $1.6B dilutive offering reversed the gains.
Healthcare
SEISMIC
Aug 236 min read
Merck Surges 12% on Landmark Melanoma Vaccine Win
Merck surged 12.6% on August 19 as a Phase 3 mRNA melanoma vaccine with Moderna cleared key endpoints, marking the first neoantigen therapy to succeed at that stage and easing fears about…
Healthcare
SEISMIC
Aug 235 min read
MRNA Surges 177% on mRNA Cancer Vaccine Trial Win
Moderna shares posted a historic single-session gain after intismeran cleared its Phase 3 melanoma primary endpoint, triggering an $8 billion short squeeze and redefining the outlook for biotech…
Healthcare
MAJOR
Aug 65 min read
Moderna mFLUSIVA: FDA Clears First mRNA Flu Shot
Moderna's mFLUSIVA becomes the first FDA-approved mRNA flu vaccine, cleared Aug. 5, 2026 for adults 50 and older, lifting MRNA shares nearly 4% to $56.99.
Markets
Jun 277 min read
MRNA Stock Leads Healthcare Rally as Chip Stocks Drop
Moderna shares surged 48% in June as an FDA flu vaccine endorsement and sector rotation away from semiconductors lifted healthcare and biotech stocks broadly.